Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
DetailsBio-Theraand STADA h ave reached an exclusive commercialization and license agreement forBAT2506, a biosimilar candidate to Simponi ® (golimumab) Bio-Thera will maintain responsibility fordevelopment, manufacturing, and supply of BAT2506 STADA willhave exclusive rights to commercialize the product ...
GUANGZHOU, China - Bio-Thera Solutions (688177.S H ), a commercial-stage biopharmaceutical company developinginnovative therapies and biosimilars, announced that its partner, Biogen Inc.(Nasdaq: BIIB) officially launched TOFIDENCE (tocilizumab-bavi) intravenousformulation, a biosimilar monoclonal an...
Guangzhou, China -- Bio-Thera Solutions(688177:SH), a commercial-stage biopharmaceutical company developing a pipelineof innovative therapies and biosimilars, today announced receiving INDclearance from the US FDA for a phase II Study for BAT8006, an innovative AntibodyDrug Conjugate (ADC) targeting...
